RxSight, Inc. (NASDAQ:RXST - Get Free Report) insider Ilya Goldshleger sold 3,100 shares of the company's stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $49.78, for a total transaction of $154,318.00. Following the transaction, the insider now owns 42,246 shares in the company, valued at approximately $2,103,005.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Ilya Goldshleger also recently made the following trade(s):
- On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total transaction of $155,529.45.
- On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.19, for a total transaction of $155,589.00.
- On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total transaction of $155,279.00.
- On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total value of $149,606.00.
- On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $48.01, for a total value of $148,831.00.
- On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.02, for a total value of $151,962.00.
- On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $49.29, for a total value of $153,045.45.
- On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $52.67, for a total transaction of $163,277.00.
- On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $53.19, for a total transaction of $164,889.00.
- On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The stock was sold at an average price of $39.25, for a total transaction of $353,250.00.
RxSight Stock Up 0.9 %
$20 = Ounce of Gold?
From Monument Traders Alliance | Ad
I've discovered a way to get exposure to MORE than an ounce of gold... for under $20.
It's not bullion. It's not ETFs. And it's certainly not crypto.
Click here to find out why this is my favorite gold stock.
NASDAQ:RXST opened at $50.47 on Friday. The company has a market cap of $1.87 billion, a P/E ratio of -40.06 and a beta of 1.20. RxSight, Inc. has a twelve month low of $20.66 and a twelve month high of $66.54. The business has a 50 day moving average price of $52.12 and a two-hundred day moving average price of $53.82.
RxSight (NASDAQ:RXST - Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.06. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The firm had revenue of $34.89 million for the quarter, compared to analyst estimates of $32.33 million. During the same period in the previous year, the business earned ($0.40) EPS. The company's revenue was up 67.6% compared to the same quarter last year. As a group, analysts anticipate that RxSight, Inc. will post -0.81 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts recently commented on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $66.00 price objective on shares of RxSight in a research note on Friday, September 13th. Stifel Nicolaus dropped their price target on RxSight from $70.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, August 6th. Wells Fargo & Company decreased their price objective on RxSight from $68.00 to $54.00 and set an "overweight" rating for the company in a research report on Tuesday, August 6th. BTIG Research raised their target price on shares of RxSight from $72.00 to $73.00 and gave the stock a "buy" rating in a report on Monday, July 15th. Finally, Oppenheimer cut their price target on shares of RxSight from $72.00 to $65.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 6th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, RxSight currently has a consensus rating of "Buy" and an average price target of $60.14.
Check Out Our Latest Analysis on RxSight
Institutional Trading of RxSight
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Marshall Wace LLP bought a new position in RxSight in the second quarter valued at approximately $19,512,000. Driehaus Capital Management LLC grew its stake in shares of RxSight by 74.9% in the second quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company's stock valued at $42,490,000 after buying an additional 302,367 shares in the last quarter. Baillie Gifford & Co. grew its position in shares of RxSight by 438.8% in the 2nd quarter. Baillie Gifford & Co. now owns 358,215 shares of the company's stock valued at $21,554,000 after acquiring an additional 291,733 shares during the period. William Blair Investment Management LLC acquired a new position in shares of RxSight during the 2nd quarter worth about $14,942,000. Finally, M&G Plc acquired a new position in shares of RxSight during the 1st quarter worth about $7,354,000. Institutional investors and hedge funds own 78.78% of the company's stock.
RxSight Company Profile
(
Get Free Report)
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
